FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2192853737> ?p ?o ?g. }

• W2192853737 endingPage "3691" @default.
• W2192853737 startingPage "3691" @default.
• W2192853737 abstract "Profile of nintedanib in the treatment of solid tumors: the evidence to date Niranjan Awasthi,1 Roderich E Schwarz1,2 1Department of Surgery, Indiana University School of Medicine, South Bend, IN, USA; 2Indiana University Health Goshen Center for Cancer Care, Goshen, IN, USA Abstract: Angiogenesis is an essential process for tumor growth and metastasis, and remains a promising therapeutic target process in cancer treatment for several cancer types. Bevacizumab, a monoclonal antibody that targets vascular endothelial growth factor (VEGF), was the first antiangiogenic agent approved for cancer therapy. Novel antiangiogenic agents, such as sunitinib, sorafenib, pazopanib, or vandetanib that target additional proangiogenic signaling pathways beyond VEGF, have also been approved for the treatment of various malignant diseases. While most of these agents are approved in combination with cytotoxic chemotherapy for indications including metastatic colorectal cancer, non-small-cell lung cancer, breast cancer, renal cell carcinoma (RCC), and gastric cancer, some are used as approved monotherapy for advanced RCC, hepatocellular carcinoma and medullary thyroid cancer. Major challenges to the success of antiangiogenic therapy include associated toxicity risks, limitation of efficacy through the possible development of resistance and induction or promotion of metastatic progression. Nintedanib (formally known as BIBF 1120) is a triple angiokinase inhibitor of VEGF, fibroblast growth factor, platelet-derived growth factor signaling with lesser activity against RET, Flt-3, and Src. Through this unique targeting profile nintedanib has demonstrated significant antitumor activity in several tumor types in preclinical studies. Nintedanib has also shown promising clinical efficacy in combination with docetaxel and has been approved for treating patients with locally advanced and metastatic non-small-cell lung cancer in Europe. Nintedanib has also been found to be clinically promising in terms of efficacy and safety in several other solid tumors including ovarian cancer (Phase III), RCC (Phase II), and prostate cancer (Phase II). This review article provides a comprehensive summary of the preclinical and clinical efficacy of nintedanib in the treatment of solid tumors. Keywords: nintedanib, BIBF 1120, angiogenesis, VEGF, tyrosine kinase inhibitors" @default.
• W2192853737 created "2016-06-24" @default.
• W2192853737 creator A5006708086 @default.
• W2192853737 creator A5047602817 @default.
• W2192853737 date "2015-12-01" @default.
• W2192853737 modified "2023-09-29" @default.
• W2192853737 title "Profile of nintedanib in the treatment of solid tumors: the evidence to date" @default.
• W2192853737 cites W1509846886 @default.
• W2192853737 cites W1539571840 @default.
• W2192853737 cites W1595998158 @default.
• W2192853737 cites W1615627891 @default.
• W2192853737 cites W1965727465 @default.
• W2192853737 cites W1967600348 @default.
• W2192853737 cites W1971440301 @default.
• W2192853737 cites W1974903851 @default.
• W2192853737 cites W1977999028 @default.
• W2192853737 cites W1978139448 @default.
• W2192853737 cites W1979594711 @default.
• W2192853737 cites W1982047105 @default.
• W2192853737 cites W1991853425 @default.
• W2192853737 cites W1999966467 @default.
• W2192853737 cites W2010589478 @default.
• W2192853737 cites W2012242068 @default.
• W2192853737 cites W2014370165 @default.
• W2192853737 cites W2014576285 @default.
• W2192853737 cites W2027239974 @default.
• W2192853737 cites W2033957860 @default.
• W2192853737 cites W2038233531 @default.
• W2192853737 cites W2039013742 @default.
• W2192853737 cites W2042543967 @default.
• W2192853737 cites W2051151803 @default.
• W2192853737 cites W2054956616 @default.
• W2192853737 cites W2071185061 @default.
• W2192853737 cites W2076415360 @default.
• W2192853737 cites W2089756110 @default.
• W2192853737 cites W2102056525 @default.
• W2192853737 cites W2104607769 @default.
• W2192853737 cites W2104759721 @default.
• W2192853737 cites W2105246037 @default.
• W2192853737 cites W2110121929 @default.
• W2192853737 cites W2112940666 @default.
• W2192853737 cites W2115005218 @default.
• W2192853737 cites W2115735904 @default.
• W2192853737 cites W2118256381 @default.
• W2192853737 cites W2118678876 @default.
• W2192853737 cites W2119281341 @default.
• W2192853737 cites W2119501407 @default.
• W2192853737 cites W2122956665 @default.
• W2192853737 cites W2123312554 @default.
• W2192853737 cites W2124143152 @default.
• W2192853737 cites W2125212831 @default.
• W2192853737 cites W2125447919 @default.
• W2192853737 cites W2126275851 @default.
• W2192853737 cites W2126318680 @default.
• W2192853737 cites W2128178813 @default.
• W2192853737 cites W2131862721 @default.
• W2192853737 cites W2132365366 @default.
• W2192853737 cites W2134657639 @default.
• W2192853737 cites W2138871107 @default.
• W2192853737 cites W2140088548 @default.
• W2192853737 cites W2140856191 @default.
• W2192853737 cites W2142656868 @default.
• W2192853737 cites W2143852804 @default.
• W2192853737 cites W2144429930 @default.
• W2192853737 cites W2145835533 @default.
• W2192853737 cites W2147834058 @default.
• W2192853737 cites W2149456801 @default.
• W2192853737 cites W2154502317 @default.
• W2192853737 cites W2156268500 @default.
• W2192853737 cites W2158366593 @default.
• W2192853737 cites W2160724351 @default.
• W2192853737 cites W2162424705 @default.
• W2192853737 cites W2166788033 @default.
• W2192853737 cites W2169199162 @default.
• W2192853737 cites W2170030318 @default.
• W2192853737 cites W2182450251 @default.
• W2192853737 cites W2403815535 @default.
• W2192853737 cites W4252851641 @default.
• W2192853737 doi "https://doi.org/10.2147/ott.s78805" @default.
• W2192853737 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4677757" @default.
• W2192853737 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26677336" @default.
• W2192853737 hasPublicationYear "2015" @default.
• W2192853737 type Work @default.
• W2192853737 sameAs 2192853737 @default.
• W2192853737 citedByCount "55" @default.
• W2192853737 countsByYear W21928537372016 @default.
• W2192853737 countsByYear W21928537372017 @default.
• W2192853737 countsByYear W21928537372018 @default.
• W2192853737 countsByYear W21928537372019 @default.
• W2192853737 countsByYear W21928537372020 @default.
• W2192853737 countsByYear W21928537372021 @default.
• W2192853737 countsByYear W21928537372022 @default.
• W2192853737 countsByYear W21928537372023 @default.
• W2192853737 crossrefType "journal-article" @default.
• W2192853737 hasAuthorship W2192853737A5006708086 @default.
• W2192853737 hasAuthorship W2192853737A5047602817 @default.
• W2192853737 hasBestOaLocation W21928537371 @default.
• W2192853737 hasConcept C121608353 @default.

• next